explore -WSS

explore

author：comprehensive 2025-09-28 23:05:40 - browse：889

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Duchenne patients, backed by ‘dark money’ group, to debate drug prices

focus

WSS

Can food be medicine? And other questions about a new push

FDA struggles to regulate food additives, sometimes for decades

Will Ozempic

PhRMA sues HHS over Medicare drug price negotiation

4th of July breaks record for highest global temperature ever measured

New case study details death in closely watched Alzhiemer's trial

focus

explore

focus

How to save PrEP access — and even expand it

STAT Readout Newsletter: Today's biggest biotech updates

Sports medicine is finally prioritizing gender equality

New case study details death in closely watched Alzhiemer's trial

How one medical school became remarkably diverse

Will Ozempic

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How climate

The cancer drug shortage isn’t new — and neither are the solutions

Option Care buys Amedisys in $3.6 billion home care deal

focus

RaDonda Vaught case: a double standard for nurses, physicians

Brain 'hot spot' may explain why African Americans feel greater pain

STAT Summit: Michael J. Fox on progress in Parkinson's research

Van's Gluten Free Original Waffles recalled for possible wheat allergen

FDA struggles to regulate food additives, sometimes for decades

NIH confirmation hearing shows politicization of research

entertainment

explore

hotspot

Wikipedia